These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Synthetic drugs: the new low-cost landscape of drugs]. Karila L, Petit A, Cottencin O, Coscas S, Reynaud M. Rev Prat; 2012 May; 62(5):664-6. PubMed ID: 22730798 [Abstract] [Full Text] [Related]
3. Exploratory comparative study on the diffusion of synthetic cannabinoids and synthetic cathinones. Arfken CL, Owens D, Madeja C, DeAngelis C. J Psychoactive Drugs; 2014 May; 46(5):362-8. PubMed ID: 25364986 [Abstract] [Full Text] [Related]
4. Alarm over synthetic cannabinoids. Underwood E. Science; 2015 Jan 30; 347(6221):473. PubMed ID: 25635070 [No Abstract] [Full Text] [Related]
5. Some new psychoactive substances: precursor chemicals and synthesis-driven end-products. Collins M. Drug Test Anal; 2011 Jan 30; 3(7-8):404-16. PubMed ID: 21755608 [Abstract] [Full Text] [Related]
6. Toxicology and management of novel psychoactive drugs. Kersten BP, McLaughlin ME. J Pharm Pract; 2015 Feb 30; 28(1):50-65. PubMed ID: 25261428 [Abstract] [Full Text] [Related]
7. New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 ('Blue Mystic'). Schifano F, Deluca P, Agosti L, Martinotti G, Corkery JM, Alex B, Caterina B, Heikki B, Raffaella B, Anna C, Lucia DF, Dorte DR, Magi F, Susana F, Irene F, Claude G, Lisbet H, Lene SJ, Mauro L, Christopher L, Aino M, Teuvo P, Milena P, Salman R, Damien R, Angela RM, Francesco R, Norbert S, Holger S, Josep T, Marta T, Francesco Z, Psychonaut 2002 Research Group. J Psychopharmacol; 2005 Nov 30; 19(6):675-9. PubMed ID: 16272191 [Abstract] [Full Text] [Related]
8. Case series of 21 synthetic cathinones abuse. Batisse A, Fortias M, Bourgogne E, Grégoire M, Sec I, Djezzar S. J Clin Psychopharmacol; 2014 Jun 30; 34(3):411-3. PubMed ID: 24743721 [No Abstract] [Full Text] [Related]
10. The NBOMe series: a novel, dangerous group of hallucinogenic drugs. Ninnemann A, Stuart GL. J Stud Alcohol Drugs; 2013 Nov 30; 74(6):977-8. PubMed ID: 24172126 [No Abstract] [Full Text] [Related]
13. The behavioral profile of spice and synthetic cannabinoids in humans. Müller HH, Kornhuber J, Sperling W. Brain Res Bull; 2016 Sep 30; 126(Pt 1):3-7. PubMed ID: 26548494 [Abstract] [Full Text] [Related]
14. A new stimulant of abuse: 5-(2-aminopropyl)indole. Coppola M, Mondola R. Am J Psychiatry; 2013 Feb 30; 170(2):226. PubMed ID: 23377642 [No Abstract] [Full Text] [Related]
15. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Young AC, Schwarz E, Medina G, Obafemi A, Feng SY, Kane C, Kleinschmidt K. Am J Emerg Med; 2012 Sep 30; 30(7):1320.e5-7. PubMed ID: 21802885 [Abstract] [Full Text] [Related]
16. Acute reactions to drugs of abuse. Med Lett Drugs Ther; 1996 May 10; 38(974):43-6. PubMed ID: 8628181 [No Abstract] [Full Text] [Related]
17. Arylethylamine psychotropic recreational drugs: a chemical perspective. Freeman S, Alder JF. Eur J Med Chem; 2002 Jul 10; 37(7):527-39. PubMed ID: 12126772 [Abstract] [Full Text] [Related]
18. A "krokodil" emerges from the murky waters of addiction. Abuse trends of an old drug. Katselou M, Papoutsis I, Nikolaou P, Spiliopoulou C, Athanaselis S. Life Sci; 2014 May 02; 102(2):81-7. PubMed ID: 24650492 [Abstract] [Full Text] [Related]
19. Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues. Schep LJ, Slaughter RJ, Hudson S, Place R, Watts M. Hum Exp Toxicol; 2015 May 02; 34(5):557-60. PubMed ID: 25233895 [Abstract] [Full Text] [Related]
20. Drug Use Among Young People. Carter D. Am J Nurs; 2015 Dec 02; 115(12):20. PubMed ID: 26600347 [Abstract] [Full Text] [Related] Page: [Next] [New Search]